



(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
25.06.1997 Bulletin 1997/26

(51) Int Cl.⁶: **G01N 15/14**

(21) Application number: 96402789.0

(22) Date of filing: 18.12.1996

(84) Designated Contracting States:
DE FR GB IT

(30) Priority: 19.12.1995 JP 350713/95

(71) Applicant: **TOA MEDICAL ELECTRONICS CO.,
Ltd.**
Kobe-shi, Hyogo 650 (JP)

(7.2) Inventors:

- Nakamoto, Hiroyuki
Kobe-Shi, Hyogo 651-21 (JP)
- Katayama, Masayuki
Miki-shi, Hyogo 673-04 (JP)


(74) Representative: **Orès, Bernard et al**
Cabinet ORES
6, Avenue de Messine
75008 Paris (FR)

(54) **Analyzer for analyzing urine material components**

(57) An analyzer for analyzing urine material components includes: a sheath flow cell for forming a sample stream containing the urine material components; a light source for illuminating the sample stream; a section for detecting optical information from the illuminated material component particles; and an analyzing section for analyzing the material components; the analyzing section including a parameter extracting section for extract-

ing parameters from the detected optical information, a section for generating a distribution diagram for the material components on the basis of the extracted parameters, a section for inputting an expectative domain of a particular material component in the distribution diagram, and a warning section for giving a warning when a cluster of data points of the particular material component deviates from the expectative domain by more than a predetermined degree.

FIG. 1



Description**BACKGROUND OF THE INVENTION**5 **FIELD OF THE INVENTION**

The present invention relates to an analyzer for analyzing urine material components and, more particularly, to an analyzer for analyzing blood cells, casts, mucous threads and the like in urine.

10 **DESCRIPTION OF RELATED ART**

Hitherto known as particle analyzers are an optical particle counting apparatus which is adapted to determine the number of particles on the basis of a scattergram generated by measuring forward or lateral fluorescent light and scatter light from illuminated stained particles, and an electrical-resistance-type particle counter which is adapted to determine the numbers of particles on a size-by-size basis by inserting a needle member into an orifice (see Japanese Unexamined Patent Publication No. 4-337459 (1992) and European Unexamined Patent Publication No. 242971A2).

Where a urine sample which includes many kinds of particles (material components) is to be analyzed by means of such a prior art apparatus, however, the qualitative and quantitative analyses of the particles are difficult because domains of the respective kinds of particles overlap with each other in a scattergram.

20 **SUMMARY OF THE INVENTION**

In view of the foregoing, it is an object of the present invention to provide an analyzer for analyzing urine material components which is capable of warning of a reduction in the accuracy of the material component analysis by determining the degree of overlapping of domains of the respective material components in a scattergram.

In accordance with the present invention, there is provided an analyzer for analyzing urine material components which comprises: a sheath flow cell for forming a sample stream by surrounding a sample liquid containing particles of the urine material components with a sheath fluid; a light source for illuminating the sample stream; a photodetector section for detecting optical information from the illuminated material component particles; and an analyzing section for analyzing the material components on the basis of the detected optical information; the analyzing section including a parameter extracting section for extracting a plurality of parameters from the detected optical information, a distribution diagram generating section for generating a distribution diagram for the material components on the basis of the extracted parameters, an inputting section for inputting discrimination conditions for discriminating a predetermined material component from the other material components, and a warning section for warning that data points of the other material components are possibly present in a domain of the predetermined material component in the distribution diagram if the data points of the material components in the distribution diagram do not satisfy the discrimination conditions.

40 **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 is a schematic diagram illustrating the construction of an analyzer in accordance with one embodiment of the present invention;

Fig. 2 is a sectional view of an orifice of a flow cell of the analyzer shown in Fig. 1;

Fig. 3 is a block diagram illustrating the electrical construction of an analyzing section of the analyzer;

Fig. 4 is a block diagram illustrating the construction of a data processing section shown in Fig. 3;

Fig. 5 is a flow chart for explaining an operation to be performed by the data processing section;

Figs. 6 to 8 are scattergrams for explaining the operation of the data processing section;

Figs. 9 to 11 are diagrams for explaining the operation of the data processing section;

Figs. 12 to 15 are scattergrams for explaining the operation of the data processing section;

Figs. 16 and 17 are scattergrams for explaining an operation to be performed by a warning section of the analyzer;

Fig. 18 is a histogram for explaining the operation of the warning section;

Fig. 19 is a histogram of erythrocytes;

5 Fig. 20 is a scattergram for explaining domains of respective material components;

Fig. 21 is a diagram illustrating a cast;

10 Fig. 22 is a diagram illustrating the waveform of scatter light pulses;

Fig. 23 is a diagram illustrating the waveform of fluorescent light pulses; and

Figs. 24 and 25 are histograms of erythrocytes in a nonhemolytic state, erythrocytes in a hemolytic state and bacteria.

15 DESCRIPTION OF THE PREFERRED EMBODIMENT

Exemplary material components (particles) to be analyzed by means of the analyzer of the present invention include blood cells, crystals, casts, epithelial cells and bacteria contained in human urine. The particles of the urine
20 material components may be pretreated with a fluorescent dye or other labeling agents. Accordingly, the analyzer may further include a pretreatment section for pretreating the particles of the urine material components with such a fluorescent dye or labeling agent before a urine sample is supplied to the sheath flow cell.

The blood cells include erythrocytes and leukocytes. The erythrocytes are often observed in urine sampled from patients of nephroureteric diseases, hemorrhagic diseases, leukemia and the like. The leukocytes are often observed
25 in urine sampled from patients of nephric and ureteric infectious diseases, nephrophthisis and the like.

The crystals include crystals of uric acid, urates and calcium oxalate contained in acidic urine, and crystals of ammonium magnesium phosphate, calcium carbonate and ammonium urate contained in alkaline urine, and crystals of DHA (2,8-dihydroxyadenine) which are often observed in urine sampled from patients of APRT deficiency and are likely to cause urinary calculus.

30 The casts are such that hemocytes and uriniferous epitheliocytes are enclosed in a base of Tamm-Horsfall mucoprotein agglutinated in uriniferous tubules in the presence of a small amount of plasma protein (albumin). The term "cast" comes from the fact that the casts are formed in the uriniferous tubules as a casting mold. The casts are also called "cylinders" in view of their shape. The presence of casts implies temporary occlusion of the uriniferous tubules, and is an important symptom suggesting a nephric disorder. Particularly, the detection of casts containing hemocytes,
35 epitheliocytes and the like has an important clinical meaning.

The epithelial cells include squamous epitheliocytes and transitional epitheliocytes. The squamous epitheliocytes are extremely thin cells in a circular or polygonal shape exfoliated from the internal surface of urethra. The transitional epitheliocytes are cells having various shapes such as pare-like shape and spindle-like shape and constituting internal surfaces of renal pelvis, urethra, bladder and internal urethral opening.

40 The bacteria are herein meant by various bacteria contained in urine sampled from patients of urocystitis or pyelitis, for example.

The sheath flow cell according to the present invention preferably includes two cells, i.e., an upper cell and a lower cell, communicating through an orifice. The sheath flow cell is adapted to form a sample liquid containing particles into a sample stream by a hydrodynamic effect produced by surrounding the sample liquid with a sheath flow, whereby the
45 particles in the sample liquid are passed in line through the orifice.

The sheath flow cell allows the sample liquid to pass through the orifice, for example, at a rate of 0.5 to 10 m/sec.

The light source projects a light beam from the outside of the flow cell to a particle passing through the orifice, a particle just entering the orifice, or a particle just exiting out of the orifice. A laser light source (excluding a pulse light source) adapted for continuous illumination is preferably used as the light source in combination with a condenser lens.
50 The width of the beam (measured in a flow direction) is preferably 5 to 30 μ m.

The photodetector section detects optical information, i.e., scatter light and fluorescent light from particles illuminated with the light beam, and converts the optical information into electrical pulse signals. Usable for the photodetector section are a photodiode, a phototransistor, a photomultiplier tube and the like.

55 The analyzing section is preferably comprised of a microcomputer or a personal computer including a CPU, a ROM and a RAM.

The parameter extracting section extracts, for example, a fluorescent light intensity FI and a scatter light intensity Fsc from peak amplitudes of the respective pulse signals indicative of the detected fluorescent light and scatter light, and extracts a fluorescent light emission duration (fluorescent light pulse width) Flw and a scatter light emission duration

(scatter light pulse width) Fscw from pulse widths of the respective signals. More specifically, a peak hold circuit is employed for the extraction of the peak amplitudes, and a counter circuit is employed for the extraction of the pulse widths.

The extracted parameter data are each converted into distribution data $F(X)$ in a parameter space. The distribution data is represented as frequency data $F(X_1, X_2, \dots, X_m)$ at a point defined by coordinates (X_1, X_2, \dots, X_m) in an m -dimensional parameter space which is defined by m (e.g., 2) parameters X_1, X_2, \dots, X_m selected from n parameters X_n as required. The distribution diagram generating section generates a distribution diagram (scattergram) with the parameters X_1, X_2, \dots, X_m plotted as the coordinates.

Where a urine sample is to be analyzed, many kinds of urine material component particles appear in a scattergram with a wide variation in the number thereof and with a wide variation in the form thereof (e.g., particles of one material component may be damaged to different degrees). In addition, the number and form of particles of each material component are likely to change (due to proliferation of bacteria, progress of hemolysis, or precipitation of crystals) with the lapse of time after the sampling of the urine. The special considerations to the urine sample make it difficult to analyze the urine material components on the basis of the scattergram in comparison with the analysis of a blood sample.

For example, erythrocytes are hardly observed in urine sampled from a healthy person, but observed in hematuria, and the concentration thereof is higher than several dozens to several thousands $/\mu\text{l}$. The difference in the number of erythrocytes is represented as a difference in the frequency of occurrence in a scattergram.

Urine erythrocytes are observed in various forms, e.g., those in a nonhemolytic state which sustain little damage and contain inner substances, and those in a hemolytic state which are damaged so heavily that almost all inner substances thereof are effused. The presence of erythrocytes in difference forms is represented as a difference in the location of data points or as an expanse of an erythrocyte domain in a scattergram.

With the lapse of time after the urine sampling, hemolysis may progress in acidic urine, bacteria may proliferate in bacteriuria, and crystals may grow and precipitate if the urine sample is stored at a low temperature. This results in a complicated distribution configuration in the scattergram in which a plurality of peaks are present in a single distribution area (domain). Therefore, it is difficult to determine the attribution of particles of the urine material components with high accuracy.

For example, data points of various crystals are located within the erythrocyte domain in the scattergram, thereby reducing the accuracy of measurement of the erythrocyte number.

To overcome this problem, the analyzing section according to the present invention analyzes the measurement accuracy by extracting distribution characteristics of a material component regarded as the erythrocyte. Where calcium oxalate crystal is contained in the urine, for example, a domain of the calcium oxalate crystal mostly overlaps the erythrocyte domain in the scattergram. In such a case, the analyzing section analyzes the measurement accuracy by detecting the domain of the calcium oxalate crystal which extends to a higher Fsc level than the erythrocyte domain. Where DHA crystal is contained in the urine, the domain of the DHA crystal extends across the erythrocyte domain. In such a case, the analyzing section analyzes the measurement accuracy by detecting a broader erythrocyte distribution range in a histogram generated by using one of the two parameters employed in the scattergram.

More specifically, a forward scatter light intensity Fsc and a fluorescent light intensity FI obtained by measuring the urine material components are used as the parameters for generation of the scattergram. Then, an upper limit of the forward scatter light intensity Fsc for the erythrocyte distribution in the scattergram is set. The accuracy of the measurement of the erythrocyte number is evaluated on the basis of the frequency or rate of data points of material components located at levels higher than the upper limit in the scattergram.

Alternatively, a histogram is generated by using one parameter, e.g., the fluorescent light intensity FI, in the scattergram, and then a distribution range in the histogram is determined. The accuracy of the measurement of the erythrocyte number is evaluated on the basis of the distribution range.

Thus, the present invention allows for the determination of the accuracy of analysis of a particular material component on the basis of a distribution diagram.

In accordance with another aspect of the present invention, an analyzer for analyzing urine material components comprises: a sheath flow cell for forming a sample stream by surrounding a sample liquid containing particles of the urine material components with a sheath fluid; a light source for illuminating the sample stream; a photodetector section for detecting optical information from the illuminated material component particles; and an analyzing section for analyzing the material components on the basis of the detected optical information; the analyzing section including a parameter extracting section for extracting a parameter from the detected optical information, a distribution section for generating a histogram on the basis of the extracted parameter, and a warning section for giving a warning when the ratio of a distribution range to a maximum frequency in the generated histogram exceeds a predetermined value.

Also, the analyzing section of the present invention may further comprise a function of discriminating hemolytic-state erythrocytes from other urine material components and computing the total number of erythrocytes including the hemolytic-state erythrocytes, on the basis of the generated distribution diagram.

In addition, the analyzing section of the present invention may further comprise a function of judging whether or not a material component particle being analyzed is a cast, on the basis of location of a data point of the material component particle in the generated distribution diagram.

The details of the above two functions are described in our copending US and EP patent applications entitled "ANALYZER FOR ANALYZING URINE MATERIAL COMPONENTS" corresponding to Japanese patent applications No. HEI 7(1995)-350712 and No. HEI 7(1995)-350714 filed on the same date as the Japanese patent application corresponding to the instant application, and are relied upon and incorporated by reference in this application.

The present invention will hereinafter be described by way of a preferred embodiment thereof with reference to the attached drawings. It should be noted that the present invention is not limited by the embodiment.

Fig. 1 is a schematic diagram illustrating the construction of an analyzer according to one embodiment of the present invention. In Fig. 1, there is shown a flow cell 5 including a first cell 7a, a second cell 7b and an orifice 11 connecting the first and second cells 7a and 7b and having a cross section as shown in Fig. 2. The first cell 7a has a stainless negative electrode 12, a sample nozzle 6, and a supply port 10 from which a sheath fluid fed from a sheath fluid container 9 through a valve 8 is supplied into the first cell 7a. The second cell 7b has a platinum positive electrode 13, and a drain 14. In Fig. 1, there are also shown a suction nozzle 3 for sucking a sample liquid subjected to a pretreatment such as dilution or staining in a pretreatment section 3a, a syringe 4, and valves 1 and 2. A reference numeral 26 denotes a stream of the sample liquid injected from the sample nozzle 6.

A constant DC power supply 15 is connected between the electrodes 12 and 13. Provided in association with the power supply 15 is an amplifier 16 for amplifying an output voltage of the power supply 15 to output the amplified voltage as a signal 29.

An optical system includes an argon laser source 17, a condenser lens 18, a beam stopper 19, a collector lens 20, a light blocking plate 30 having a pin hole 21, a dichroic mirror 22, a filter 23, a photomultiplier tube 24 and a photodiode 25.

A diluent solution and a staining solution to be used for pretreatment are prepared in the pretreatment section 3a according to the prescription described below.

. Diluent solution		
Buffer agent	HEPES NaOH	50mM in an amount to adjust pH at 7.0
Osmotic pressure compensating agent	sodium propionate	in an amount to adjust osmotic pressure at 150 mOsm/kg
Chelating agent	EDTA-3K	0.4 W/W%

The electric conductivity of the diluent solution is 5 mS/cm.

. Staining solution		
First dye	DiOC6(3)	400ppm
Second fluorescent dye	EB	1600ppm

Ethylene glycol is used as a solvent.

In the pretreatment section 3a, urine 400 μ l is diluted in the above diluent solution 1160 μ l, and the above staining solution 40 μ l is added (dilution ratio = 4) for staining the urine material components at 35°C.

When the valves 1 and 2 are opened for a predetermined period, the sample liquid (containing particles of the urine material components in accordance with this preferred embodiment) is sucked from the suction nozzle 3 by a negative pressure and filled in a conduit between the valves 1 and 2.

In turn, the syringe 4 pushes out the sample liquid from the conduit between the valves 1 and 2 at a constant rate, thereby injecting the sample liquid from the sample nozzle 6 into the first cell 7a. At the same time, the valve 8 is opened so that the sheath fluid is supplied into the first cell 7a.

Thus, the sample liquid is surrounded with the sheath fluid and narrowed down by the orifice 11 for formation of a sheath flow. The orifice 11 is formed of an optical glass (including quartz glass) and has a square opening ($d=100$ to 300μ m) as shown in Fig. 2.

The formation of the sheath flow allows particles in the sample liquid to be passed one by one in line through the orifice 11. The sample liquid and the sheath fluid passed through the orifice 11 are discharged from the drain 14.

The electrical resistance between the electrodes 12 and 13 is determined by the conductance (electrical conductivity) of the sheath fluid, the opening size (cross section) and length of the orifice 11, the conductance of the sample

liquid, and the diameter of the sample liquid stream.

A constant current is passed between the electrodes 12 and 13 from the constant DC power supply 15 to generate a DC voltage, the amplitude of which is determined by the electrical resistance between the electrodes 12 and 13 and the amperage of the current. When the particles are passed through the orifice 11, the electrical resistance across the orifice 11 is changed. More specifically, only during the passage of the particles, the electrical resistance is changed, thereby pulsating the voltage generated between the electrodes 12 and 13. The maximum value of the pulsated voltage (peak amplitude of a pulse) is directly proportional to the size of a particle passing through the orifice 11. The pulse is amplified by the amplifier 16 and outputted as a resistance signal (analog pulse signal) 29.

On the other hand, a laser beam emitted from the laser source 17 is narrowed down as having an elliptical cross section by the condenser lens 18 and projected onto the sample liquid stream 26 flowing through the orifice 11. The minor axis of the elliptical cross section extending in the flow direction of the sample liquid stream is substantially equivalent to the diameter of a particle to be measured, e.g., about $10\text{ }\mu\text{m}$, and the major axis extending perpendicular to the flow direction is sufficiently greater than the particle diameter, e.g., about 100 to $400\text{ }\mu\text{m}$.

A portion of the laser beam passing through the flow cell 5 without impinging on the particle in the sample liquid is blocked by the beam stopper 19. Forward scatter light and forward fluorescent light from the particle illuminated with the laser beam are collected by the collector lens 20, and pass through the pin hole 21 of the light blocking plate 30, reaching the dichroic mirror 22.

The fluorescent light which has a greater wavelength than the scatter light passes through the dichroic mirror 22, and then passes through the filter 23, whereby scatter light is filtered away therefrom. The fluorescent light is detected by the photomultiplier tube 24, which outputs a fluorescent light signal (analog pulse signal) 27. The forward scatter light is reflected by the dichroic mirror 22, and then received by the photodiode 25, which outputs a scatter light signal (analog pulse signal) 28.

Fig. 3 is a block diagram illustrating the electrical construction of an analyzing section 100 which processes the fluorescent light signal 27, the scatter light signal 28 and the resistance signal 29 thus obtained. A parameter extracting section 200 includes amplifiers 31 to 33, direct current regenerator circuits 34 and 35, comparators 37 and 39, peak hold circuits 38 and 50, a clock generator 52, counters 42 and 44, A/D converters 43, 45 and 51, and a counter control circuit 46. In Fig. 3, there are also shown a data storage 47, a data processing section 48 and a display 49.

There will next be described a signal processing operation to be performed by the analyzing section having such a construction.

The scatter light pulse signal 28 is amplified by the amplifier 32, and the DC component thereof is fixed by the DC regenerator circuit 35. A pulse signal S2 outputted from the DC regenerator circuit 35 is compared with a threshold Th1 (see Fig. 22) by the comparator 39. A period (pulse width) during which the threshold Th1 is exceeded is measured as a scatter light emission duration (scatter light pulse width) Fscw by the counter 44. The peak amplitude of the scatter light signal is held by the peak hold circuit 50, and A/D-converted by the A/D converter 51 to provide a scatter light intensity Fsc.

The fluorescent light pulse signal 27 is amplified by the amplifier 31, and the DC component thereof is fixed by the DC regenerator circuit 34. A pulse signal S1 outputted from the DC regenerator circuit 34 is compared with a threshold Th2 (see Fig. 23) by the comparator 37. A period during which the threshold Th2 is exceeded is measured as a fluorescent light emission duration (scatter light pulse width) Flw by the counter 42. The peak amplitude of the fluorescent light signal 27 is held by the peak hold circuit 38, and A/D-converted by the A/D converter 43 to provide a fluorescent light intensity FI.

The resistance pulse signal 29 is amplified by the amplifier 33. The peak amplitude thereof (pulse peak amplitude) is held by the sample hold circuit 40, and converted into a digital value by the A/D converter 45.

The digitized output signals of the counters 42 and 44 and the A/D converters 43, 45 and 51 are stored in the data storage 47 and, at the same time, sent to the data processing section 48 for determination of attribution of the respective urine material component particles.

More specifically, the attribution of the respective particles (erythrocyte, casts such as glass cast and inclusion cast, and the like) is determined on the basis of the distribution diagrams (histogram and scattergram). The particles in each category are counted, and the number thereof is converted on the basis of per-microliter sample liquid. The result and the distribution diagrams are displayed in the display 49.

Fig. 4 is a block diagram illustrating the construction of the data processing section 48. An inputting section 61 is adapted to preliminarily input various conditional data such as conditional values and expectative domains, and comprised of a keyboard and a mouse, for example.

A condition storing section 61a stores the inputted conditional data. A distribution diagram generating section 62 generates distribution diagrams, i.e., FI-Fsc, Fscw-FI and Fscw-Flw scattergrams and FI, Fsc, Flw and Fscw histograms, on the basis of the parameter information stored in the data storage 47. An extracting section 63 extracts coordinate data and domains from the distribution diagrams generated by the distribution diagram generating section 62.

A domain determining section 64 determines domains of the respective material components in the distribution diagrams generated by the distribution diagram generating section 62. A computing section 65 performs various arithmetic operations, and counts data points of a material component in each domain. A warning section 66 gives a warning when an erroneous result on the data clustering or the counting is detected. A judging section 67 determines the kind of the material component particles in the domain. The computation results from the computing section 65 and the warning from the warning section 66 are displayed in the display 49 like the distribution diagrams generated by the distribution diagram generating section 62.

There will next be described principal operations to be performed by the data processing section 48.

10 (1) Determination of domains in scattergram

In the analyzer, domains of the respective material components are defined in a scattergram for determination of the attribution of the detected material component particles. An exemplary process for the domain determination will be described with reference to the flow chart shown in Fig. 5.

15 When an FI-Fsc scattergram is generated by the distribution diagram generating section 62 and displayed as shown in Fig. 6 (Step S1), an expectative domain S0 where the maximum frequency point in erythrocyte distribution is possibly present is read out of the condition storing section 61a, and located in the FI-Fsc scattergram as shown in Fig. 7 (Step S2). It is noted that an operator can change the location of the expectative domain S0 by operating the inputting section 61.

20 In turn, the extracting section 63 sets a threshold for distribution frequency in the expectative domain S0, and extracts local maximum points P1, P2, ... each having a higher frequency than the threshold and neighboring points, as shown in Fig. 8 (Step S3).

As indicated by a solid dot in Fig. 9, the local maximum point P1 is marked as a constituent point of a domain to be determined (Step S4).

25 The marked point (solid point) is compared with its neighboring points in terms of the frequency, and then points having a lower frequency are marked as shown in Fig. 10 (Steps S5 to S7). This process sequence is repeated until no neighboring point has a lower frequency than the marked points (Step S6). Then, the cluster of the marked points is defined as an area S1, as shown in Fig. 11.

30 Where there are a plurality of local maximum points, the process sequence described above is repeated. More specifically, an area S2 for the local maximum point P2 is defined (Steps S9 to S13). Then, combined areas S1 and S2 are finally defined as the erythrocyte domain (Step S14).

Domains of the other material components are defined in the same manner, and the number of material component particles falling within each of the domains is determined by the computing section 65 and displayed in the display 49.

35 As described above, the domain determining method according to this embodiment is such that one or more local maximum points are first determined and then the domain is gradually expanded by comparing the local maximum points with their neighboring points in terms of the frequency. Therefore, the determination of the domain is not influenced by a complicated configuration of the domain, a large number of local maximum frequency points in the domain, and a small population in the domain.

40 Even if the distribution of the material component particles is slightly shifted due to a change in the sensitivity of the analyzer, the determination of the domain is not influenced by the shift of the distribution.

Further, coordinate data to be processed can be reduced by consolidating the coordinates of distribution diagrams, whereby the process is simplified for higher speed operation. Where 4x4 coordinates are consolidated, for example, the numbers of distribution diagrams and coordinate data can be reduced to 1/16.

45 (2) Analysis of erythrocytes in hemolytic state

In accordance with the present invention, erythrocytes in a hemolytic state can be analyzed (the analysis of the hemolytic-state erythrocytes is not performed in the prior-art analyzer). The analyzing process will hereinafter be described.

50 An operator operates the inputting section 61 to input expectative domains Ao, Bo and Eo where maximum frequency points for nonhemolytic-state erythrocytes, hemolytic-state erythrocytes and cryptococcoma-like eumycetes are possibly located, respectively, in an FI-Fsc scattergram as shown in Fig. 13 in the aforesaid manner. The domain determining section 64 defines an area A where data points of the nonhemolytic-state erythrocytes are mainly located, an area B where the scatter light intensity Fsc is lower than the data points of the erythrocytes in the area A and data points of the hemolytic-state erythrocytes and the cryptococcoma-like eumycetes are located, and an area E where data points of the cryptococcoma-like eumycetes alone are located, as shown in Fig. 13.

55 An expectative domain Co where the scatter light intensity Fsc is lower than the data points of the erythrocytes in the area A and data points of the hemolytic-state erythrocytes are possibly located but no data point of streptobacillus

is present is inputted from the inputting section 61, as shown in Fig. 15.

In turn, an expectative domain Do where data points of the hemolytic erythrocytes and streptobacillus are possibly located is inputted in an Fscw-FI scattergram generated by the distribution diagram generating section 62 as shown in Fig. 14. The domain determining section 64 defines an area D where data points of the hemolytic-state erythrocytes and the streptobacillus are located in the Fscw-FI scattergram.

The computing section 65 computes the number R of the data points of the nonhemolytic-state erythrocytes in the area A, the number r1 of the data points of the hemolytic-state erythrocytes simultaneously belonging to the areas C and D, the number r2 of the data points of the hemolytic-state erythrocytes in the area B, and the number Y of the data points of the cryptococcoma-like eumycetes in the area E.

The number r of the hemolytic-state erythrocytes and the total number RBC of the erythrocytes are calculated from the following equations:

$$r = r1 + r2 \quad (1)$$

$$RBC = R + r \quad (2)$$

Where the number Y of the cryptococcoma-like eumycetes exceeds a predetermined value e ($Y > e$), however, there is a possibility that the data points of the cryptococcoma-like eumycetes as well as the data points of the hemolytic-state erythrocytes are present in the area B. Therefore, the data points of the hemolytic-state erythrocytes in the area B is not taken into account, and it is considered that $r2 = 0$. On the other hand, if $Y \leq e$, it is considered that the data points in the area B are attributable to the hemolytic-state erythrocytes.

The number r of the hemolytic-state erythrocytes changes with the lapse of time. For example, the ratio of the nonhemolytic-state erythrocyte number R to the hemolytic-state erythrocyte number r is 80:20 in an Fsc histogram (Fig. 24), but the ratio changes into 20:80 with the lapse of time as shown in Fig. 25.

Referring to Fig. 25, a bacteria frequency distribution J significantly overlaps a hemolytic-state erythrocyte frequency distribution r and, hence, the number r of the hemolytic-state erythrocytes cannot accurately be determined. More specifically, if the hemolytic-state erythrocyte number r exceeds a predetermined level, the calculated number r may be erroneous.

Therefore, the area C is an area variably set from the inputting section 61 in consideration of the time-related change in the number of the hemolytic-state erythrocytes.

The computing section 65 computes the ratio h of the hemolytic-state erythrocytes from $h = r/(R + r)$. If the ratio h is greater than a predetermined level, the hemolytic-state erythrocyte frequency distribution overlaps the bacteria frequency distribution. Therefore, the warning section 66 judges that the data clustering is erroneous, and displays a warning in the display 49.

As describe above, the analyzer of the present invention is capable of determining the number of the hemolytic-state erythrocytes (which is not determined in the prior art), allowing for the determination of the total number of the urine erythrocytes. Further, the number of the hemolytic-state erythrocytes can accurately be determined in consideration of the time-related change thereof.

(3) Warning against erroneous analysis (erroneous data clustering)

The analyzer has a function for warning against an erroneous analysis (erroneous data clustering) as described above. In addition, when it is determined that data points of different material components are present in the same domain, the analyzer gives a warning indicative of impossibility of data clustering. An explanation will be given to the warning process, taking as an example the data clustering for the calcium oxalate crystal and the erythrocyte.

The distribution diagram generating section 62 generates an FI-Fsc distribution diagram (two-dimensional scattergram) and the domain determining section 64 determines a domain X of the calcium oxalate crystal as shown in Fig. 16. Then, the domain determining section 64 compares the domain X with the preliminarily inputted expectative domain S0 where data points of erythrocytes are possibly located. The domain X of the calcium oxalate crystal mostly overlaps the expectative erythrocyte domain S0, and extends to a higher Fsc level than the domain S0. If it is determined that a difference in the highest Fsc level between the domains X and S0 exceeds a predetermined level, the warning section 66 warns that the data clustering for the erythrocyte is impossible due to the presence of the calcium oxalate crystal.

Where DHA crystal particles are present in a urine sample, a domain Y of the DHA crystal extends across the expectative erythrocyte domain S0 as shown in an FI-Fsc scattergram of Fig. 17. Therefore, it is impossible to accurately cluster the data points of the erythrocytes.

In such a case, the warning section 66 determines the ratio b/a of a peak frequency value a to a distribution range b at a frequency level of $a/5$ in an FI histogram (Fig. 18) generated by the distribution diagram generating section 62, and compares the ratio b/a with a predetermined value. The predetermined value is set on the basis of a histogram for typical erythrocyte distribution (Fig. 19). If the ratio b/a exceeds the predetermined value, the warning section 66 warns that the data clustering for the erythrocyte is impossible due to the presence of the DHA crystal.

(4) Detection and subdivision of casts

Where the urine material components (particles) are pretreated by a staining method for staining cell membranes and nuclei, the scatter light emission duration F_{scw} and the fluorescent light emission duration F_{lw} are roughly equal to each other ($F_{scw} \approx F_{lw}$) in the case of blood cells, epitheliocytes, bacteria and crystals. In the case of casts containing protein bodies, however, the scatter light emission duration F_{scw} and the fluorescent light emission duration F_{lw} are different in the level ($F_{scw} > F_{lw}$) because the protein bodies are less stainable.

Where casts contain inclusion bodies, only the inclusion bodies are stained and, hence, the ratio of the scatter light emission duration to the fluorescent light emission duration varies depending on the density of the inclusion bodies.

By utilizing such characteristics, the analyzer subdivides the casts into two types, i.e., an inclusion cast and a glass cast (containing no inclusion).

More specifically, the length L of a cast Z as shown in Fig. 21 is directly proportional to the scatter light pulse width F_{scw} shown in Fig. 22. Where the cast Z is preliminarily stained, the lengths L_1 , L_2 and L_3 of inclusion bodies Z_1 , Z_2 and Z_3 in the cast Z are directly proportional to pulse widths F_{lw1} , F_{lw2} and F_{lw3} of fluorescent light signals, respectively, as shown in Fig. 23. It is noted that "Th1" in Fig. 22 and "Th2" in Fig. 23 are predetermined thresholds of the comparators 39 and 37, respectively, shown in Fig. 3.

In the analyzer, the relationship among F_l , F_{lw1} , F_{lw2} and F_{lw3} is represented as follows:

$$F_l = F_{lw1} + F_{lw2} + F_{lw3} \quad (3)$$

Where fluorescent light pulse widths F_{lw1} , F_{lw2} , ... F_{lwn} are obtained for a single cast, the pulse width F_{lw} for the cast is calculated as follows:

$$F_{lw} = \sum_{i=1}^n F_{lwi} \quad \dots \dots (4)$$

In an F_{scw} - F_{lw} scattergram generated by the distribution diagram generating section 62 on the basis of the pulse width F_{lw} thus obtained, an erythrocyte domain T_1 , a leukocyte domain T_2 and an epitheliocyte domain T_3 are located generally along a line L_1 , while a cast domain T_4 is separated from the domains T_1 to T_3 by a boundary line L_2 .

Therefore, the judging section 67 defines the domain T_4 located below the line L_2 as the cast domain.

Alternatively, the determination of the cast domain may be based on the coordinate data in the scattergram. That is, a cluster of coordinate data having F_{lw}/F_{scw} values smaller than the inclination of the line L_2 may be defined as the cast domain.

In general, the amount of inclusion in a cast determines the type of the cast, i.e., the inclusion cast or the glass cast (containing no inclusion).

Therefore, the line L_3 is inputted as a reference for the cast domain determination from the inputting section 61 as shown in Fig. 20. This allows the judging section 67 to define an area T_{4a} above the line L_3 as the inclusion cast domain and an area T_{4b} below the line L_3 as the glass cast domain.

In accordance with the present invention, a warning is given when the reliability of analysis data obtained from the analysis of urine material components is reduced. Therefore, highly accurate data analysis can be ensured.

Claims

1. An analyzer for analyzing urine material components, comprising:

a sheath flow cell for forming a sample stream by surrounding a sample liquid containing particles of the urine material components with a sheath fluid;

a light source for illuminating the sample stream;

a photodetector section for detecting optical information from the illuminated material component particles; and

an analyzing section for analyzing the material components on the basis of the detected optical information;
wherein the analyzing section includes:

a parameter extracting section for extracting a plurality of parameters from the detected optical information;

a distribution diagram generating section for generating a distribution diagram for the material components on the basis of the extracted parameters;

an input section for inputting a discrimination condition for discriminating a predetermined material component from the other material components; and

a warning section for warning that data points of the other material components are possibly present in a domain of the predetermined material component in the distribution diagram when data points of the material components in the distribution diagram do not satisfy the discrimination condition.

2. An analyzer as set forth in claim 1, further comprising a pretreatment section for staining the particles of the urine material components with a fluorescent dye before the sample liquid is supplied into the sheath flow cell.

3. An analyzer as set forth in claim 2, wherein the parameters to be extracted include a fluorescent light intensity and a scatter light intensity.

4. An analyzer as set forth in claim 1, wherein the predetermined material component is erythrocyte.

5. An analyzer as set forth in claim 4, wherein the other material components include calcium oxalate crystal.

6. An analyzer as set forth in claim 1,

wherein the discrimination condition to be inputted from the inputting section include an expectative domain of the predetermined material component in the distribution diagram, and

wherein the warning section gives a warning when some of the data points of the predetermined material component fall out of the expectative domain.

7. An analyzer as set forth in claim 6, further comprising a pretreatment section for staining the particles of the urine material components with a fluorescent dye before the sample liquid is supplied into the sheath flow cell.

8. An analyzer as set forth in claim 7, wherein the parameters to be extracted include a fluorescent light intensity and a scatter light intensity.

9. An analyzer as set forth in claim 7, wherein the predetermined material component is erythrocyte.

10. An analyzer as set forth in claim 9, wherein the other material components include calcium oxalate crystal.

11. An analyzer as set forth in claim 1,

wherein the discrimination conditions to be inputted from the inputting section include an upper limit of one of the parameters used for the generation of the distribution diagram, and

wherein the warning section gives a warning when some of the data points of the predetermined material component are located above the upper limit in the distribution diagram.

12. An analyzer as set forth in claim 11, wherein the one parameter is a scatter light intensity.

13. An analyzer as set forth in claim 11, wherein the predetermined material component is erythrocyte.

14. An analyzer as set forth in claim 11, wherein the other material components include calcium oxalate crystal.

15. An analyzer as set forth in claim 1,

5 wherein the distribution diagram generating section is adapted to generate a histogram for each of the material components on the basis of one of the parameters,

10 wherein the discrimination conditions to be inputted from the inputting section include the ratio of a distribution range to a maximum frequency in the histogram, and

10 wherein the warning section gives a warning when the ratio of a distribution range to a maximum frequency in a histogram for any material component other than the predetermined material component is greater than that in a histogram for the predetermined material component.

15 16. An analyzer as set forth in claim 15, further comprising a pretreatment section for staining the particles of the urine material components with a fluorescent dye before the sample liquid is supplied into the sheath flow cell.

17. An analyzer as set forth in claim 16, wherein the one parameter is a fluorescent light intensity.

20 18. An analyzer as set forth in claim 15, wherein the predetermined material component is erythrocyte.

19. An analyzer as set forth in claim 18, wherein the other material components include DHA crystal.

25 20. A method of analyzing erythrocytes using the analyzer defined in any one of claims 1 through 19.

30

35

40

45

50

55

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24





FIG. 25





(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
10.02.1999 Bulletin 1999/06

(51) Int Cl.⁶: **G01N 15/14**

(43) Date of publication A2:
25.06.1997 Bulletin 1997/26

(21) Application number: **96402789.0**

(22) Date of filing: 18.12.1996

(84) Designated Contracting States:
DE FR GB IT

(30) Priority: 19.12.1995 JP 350713/95

(71) Applicant: **TOA MEDICAL ELECTRONICS CO.,
Ltd.
Kobe-shi, Hyogo 650 (JP)**

(72) Inventors:

- Nakamoto, Hiroyuki
Kobe-Shi, Hyogo 651-21 (JP)
- Katayama, Masayuki
Miki-shi, Hyogo 673-04 (JP)


(74) Representative: **Orès, Bernard et al**
Cabinet ORES
6, Avenue de Messine
75008 Paris (FR)

(54) **Analyzer for analyzing urine material components**

(57) An analyzer for analyzing urine material components includes: a sheath flow cell for forming a sample stream containing the urine material components; a light source for illuminating the sample stream; a section for detecting optical information from the illuminated material component particles; and an analyzing section for analyzing the material components; the analyzing section including a parameter extracting section for extract-

ing parameters from the detected optical information, a section for generating a distribution diagram for the material components on the basis of the extracted parameters, a section for inputting an expectative domain of a particular material component in the distribution diagram, and a warning section for giving a warning when a cluster of data points of the particular material component deviates from the expectative domain by more than a predetermined degree.

FIG. 1



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 40 2789

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	WO 93 05478 A (BECTON DICKINSON CO) 18 March 1993 * page 15, paragraph 3 - page 16, paragraph 1 *	1-3	G01N15/14
Y	* the whole document *	4,9,13, 18,20	
Y	EP 0 514 178 A (TOA MEDICAL ELECTRONICS) 19 November 1992 * the whole document *	4,9,13, 18,20	
A	EP 0 529 666 A (OMRON TATEISI ELECTRONICS CO) 3 March 1993 * column 4, line 36 - column 5, line 19 *	1-20	
A	US 4 475 236 A (HOFFMAN ROBERT A) 2 October 1984 * column 1, line 1-57 *	1,20	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			G01N
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 2 December 1998	Examiner Müller, T
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 (03.82) (P4/001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 96 40 2789

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

02-12-1998

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9305478	A	18-03-1993	AT 151546 T	15-04-1997
			DE 69218912 D	15-05-1997
			DE 69218912 T	09-10-1997
			EP 0554447 A	11-08-1993
			ES 2102518 T	01-08-1997
			JP 2581514 B	12-02-1997
			JP 6501106 T	27-01-1994
			US 5627040 A	06-05-1997
			US 5739000 A	14-04-1998
			US 5776709 A	07-07-1998
			US 5795727 A	18-08-1998
EP 0514178	A	19-11-1992	JP 5322883 A	07-12-1993
			AU 1622492 A	19-11-1992
			CA 2068490 A	15-11-1992
			DE 69209886 D	23-05-1996
			DE 69209886 T	14-08-1996
			US 5325169 A	28-06-1994
EP 0529666	A	03-03-1993	JP 5060750 A	12-03-1993
			JP 5180831 A	23-07-1993
			US 5488469 A	30-01-1996
US 4475236	A	02-10-1984	NONE	

BEST AVAILABLE COPY